Protective Effect of Low 2-O, 3-O Desulfated Heparin (ODSH) Against LPS-Induced Acute Lung Injury in Mice
Biomolecules · 2025
DOI: 10.3390/biom15091232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Joyce Gonzales und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care, and Sleep Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA. Hauptthemen laut MEDLINE: Acute Lung Injury, Lipopolysaccharides, Heparin, Protective Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AU intramural grant program, American Heart Association-American Stroke Association, NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), are critical conditions lacking effective pharmacologic therapies. Lipopolysaccharide (LPS), a bacterial endotoxin, is a well-established trigger of ALI. Emerging evidence suggests that heparin derivatives may attenuate lung injury, but their mechanisms remain unclear.
Methods
This study evaluated the protective effects of 2-O, 3-O desulfated heparin (ODSH) in a murine model of LPS-induced ALI. Mice received LPS intratracheally with or without ODSH pre-treatment. Lung injury was assessed by bronchoalveolar lavage fluid (BALF) analysis, Evans blue dye albumin EBDA) extravasation, and histopathology.
Results
ODSH treatment significantly reduced BALF protein concentration, inflammatory cell infiltration, and EBDA leakage. ODSH preserved endothelial barrier function in vitro, as evidenced by transendothelial electrical resistance (TER) measurements in human lung microvascular endothelial cell (HLMVEC) monolayers. Histological assessment (H&E staining) and myeloperoxidase (MPO) staining demonstrated reduced lung injury and neutrophil infiltration in the ODSH group. ODSH also downregulated pro-inflammatory mediators (NF-κB, IL-6, p38 MAPK) and upregulated the anti-inflammatory cytokine IL-10.
Conclusions
ODSH mitigates LPS-induced ALI by reducing vascular permeability, neutrophilic inflammation, and pro-inflammatory signaling while enhancing IL-10 expression. These findings suggest ODSH may offer a novel therapeutic approach for treating ALI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary, Critical Care, and Sleep Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
- Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
- Cantex Pharmaceuticals, Inc., Weston, FL 33326, USA.
- GlycoMira Therapeutics, Salt Lake City, UT 84108, USA.
- Department of Medicine, Division of Pulmonary Medicine, Wake Forest University, Winston-Salem, NC 27157, USA.
- Department of Physiology, School of Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
ORCID-Profile: Rahul S Patil, Rudolf Lucas
Förderung
- AU intramural grant program
- American Heart Association-American Stroke Association
- NHLBI NIH HHS
- Dr. Michael Madaio from the Department of Internal Medicine, Augusta University Health
- Michael Madaio
- NHLBI
- AHA
Zitieren
APA
Gonzales, J., Patil, R. S., Kennedy, T. P., Umapathy, N. S., Lucas, R., & Verin, A. D. (2025). Protective Effect of Low 2-O, 3-O Desulfated Heparin (ODSH) Against LPS-Induced Acute Lung Injury in Mice. Biomolecules. https://doi.org/10.3390/biom15091232
Vancouver
Gonzales J, Patil RS, Kennedy TP, Umapathy NS, Lucas R, Verin AD. Protective Effect of Low 2-O, 3-O Desulfated Heparin (ODSH) Against LPS-Induced Acute Lung Injury in Mice. Biomolecules. 2025. doi:10.3390/biom15091232
BibTeX
@article{Gonzales2025,
author = {Gonzales, Joyce and Patil, Rahul S and Kennedy, Thomas P and Umapathy, Nagavedi S and Lucas, Rudolf and Verin, Alexander D},
title = {Protective Effect of Low 2-O, 3-O Desulfated Heparin (ODSH) Against LPS-Induced Acute Lung Injury in Mice},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15091232}
}
EUVIMED